CHRNB2

CHRNB2 encodes the β2 subunit of neuronal nicotinic acetylcholine receptors (nAChRs), primarily forming α4β2 heteropentameric ligand-gated cation channels that mediate fast cholinergic neurotransmission. Disease-causing missense mutations in the second (V287M) and third (I312M, Thr26Met) transmembrane domains produce gain-of-function receptors with markedly increased acetylcholine sensitivity, establishing this mechanism as the basis of autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) (PMID:11104662, PMID:15964197, PMID:32536355). In cancer contexts, CHRNB2 suppresses cell proliferation, migration, invasion, and epithelial–mesenchymal transition through PI3K–AKT/JAK–STAT and β-catenin pathway regulation, operating via an acetylcholine-independent mechanism (PMID:34331011, PMID:36344976).

1. 1998 Medium

   Determining the genomic structure and chromosomal location of CHRNB2 provided the essential framework for subsequent mutational analyses linking this gene to disease.

   Evidence Genomic sequencing and chromosomal mapping to chromosome 1

   PMID:9921897

   Open questions at the time

   • No functional characterization of the encoded protein was performed
   • Regulatory elements controlling CHRNB2 expression were not mapped
2. 2000 High

   Electrophysiological characterization of the V287M mutation in the M2 transmembrane domain revealed a ~10-fold increase in acetylcholine sensitivity, establishing gain-of-function as the pathogenic mechanism underlying ADNFLE.

   Evidence Functional expression of mutant and wild-type α4β2 receptors in Xenopus oocytes with electrophysiological recording

   PMID:11104662

   Open questions at the time

   • Mechanism by which increased ACh sensitivity leads to seizure generation in neural circuits was not addressed
   • Single mutation studied; generalizability to other CHRNB2 ADNFLE mutations was unknown
3. 2005 Medium

   Discovery that the I312M mutation in the M3 domain also increases ACh sensitivity extended the gain-of-function mechanism beyond the M2 domain and linked CHRNB2 mutations to cognitive phenotypes (verbal memory deficits) in addition to epilepsy.

   Evidence Functional expression assay of mutant receptor combined with clinical neuropsychological testing in mutation carriers

   PMID:15964197

   Open questions at the time

   • Single-lab study; independent replication of the cognitive phenotype not reported
   • Structural basis for how an M3 mutation increases ACh sensitivity was not resolved
4. 2020 Medium

   Characterization of the Thr26Met mutation demonstrated increased whole-cell nicotinic currents in human cell lines, confirming the gain-of-function paradigm in a mammalian expression system and showing it applies to mutations at yet another position.

   Evidence Whole-cell patch-clamp electrophysiology of α4β2 receptors reconstituted in human cell lines

   PMID:32536355

   Open questions at the time

   • Single-lab study with one mutation
   • No analysis of receptor trafficking or surface expression changes that might contribute to increased currents
5. 2021 Medium

   Loss-of-function studies revealed an unexpected role for CHRNB2 in promoting gastric cancer cell survival through PI3K–AKT and JAK–STAT signaling, broadening the gene's functional relevance beyond neuronal ion channel activity.

   Evidence CRISPR knockout, RNAi knockdown, ectopic overexpression, in vitro proliferation/invasion assays, and mouse xenograft models with pathway analysis

   PMID:34331011

   Open questions at the time

   • Whether CHRNB2's cancer role depends on ion channel function or a non-canonical mechanism was not resolved
   • Single cancer type studied in one lab
6. 2022 Medium

   Bidirectional manipulation of CHRNB2 in pancreatic cancer cells established an acetylcholine-independent suppression of migration and invasion via β-catenin pathway downregulation and EMT inhibition, defining a non-canonical signaling function.

   Evidence Transwell migration/invasion assays with CHRNB2 knockdown and overexpression; Western blot for β-catenin pathway components and EMT markers

   PMID:36344976

   Open questions at the time

   • Direct binding partners mediating the acetylcholine-independent mechanism are unidentified
   • Apparent oncogenic role in gastric cancer versus tumor-suppressive role in pancreatic cancer is unreconciled

• The structural basis for how distinct transmembrane domain mutations converge on gain-of-function, the neural circuit mechanisms linking receptor hypersensitivity to seizures, and the molecular basis of CHRNB2's acetylcholine-independent signaling in cancer remain unresolved.
• No high-resolution structure of disease-mutant α4β2 receptors
• No in vivo neural circuit-level explanation for ADNFLE pathogenesis
• Direct molecular partners mediating non-canonical cancer signaling are unknown